• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

    6/24/24 4:37:13 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARVN alert in real time by email

    - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -

    NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D.

    "It is a pleasure to welcome Andrew as our new Chief Financial Officer," said John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas. "Andrew is a seasoned executive in biopharma finance with extensive experience in strategic financial leadership. His expertise in developing robust financial strategies will be invaluable as Arvinas builds out the financial systems and infrastructure necessary to transition to a commercial-stage biotech and continues to execute multiple ongoing clinical-stage programs to prepare for a Phase 3 data readout."

    Mr. Saik has more than 20 years of biopharma finance experience, most recently serving as Chief Financial Officer at Intercept Pharmaceuticals, Inc. While at Intercept Pharmaceuticals, he led the effort to recapitalize the balance sheet by selling the international division for $450 million and then repurchasing $390 million in convertible debt with a combination of cash and stock. Prior to Intercept Pharmaceuticals, Mr. Saik was Chief Financial Officer of Vyne Therapeutics Inc., where he led a buildout of the company's finance department in the U.S., renegotiated debt obligations to provide the company with enhanced financial flexibility and helped raise over $135 million to fund operations. Prior to joining Vyne Therapeutics, Mr. Saik held CFO positions at PDS Biotechnology, Corp. (formerly Edge Therapeutics, Inc.), Vertice Pharma, LLC, and Auxilium Pharmaceuticals, Inc. Prior to Auxilium Pharmaceuticals, he was Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc., where he helped complete the acquisition of Paladin Labs and restructured $3 billion of debt into a new corporate structure.

    "I am delighted to join this dynamic team and contribute to the company's future successes," said Mr. Saik. "Arvinas has a remarkable track record in pioneering targeted protein degradation, and I believe that my experience in developing commercial strategies and guiding financial operations at late-stage companies will be instrumental as Arvinas builds and scales the financial systems and infrastructure necessary to support its ambitious growth plans and ensure the company is well-positioned as it transitions towards commercialization. This is a pivotal time for the company, and I am excited to be a part of its promising future and help build on the incredible momentum to date."

    In connection with the commencement of Mr. Saik's employment, Arvinas granted Mr. Saik an option to purchase 94,418 shares of common stock and a restricted stock unit award with respect to 61,409 shares of common stock on June 24, 2024, as an inducement material to entering into employment with Arvinas. The option and restricted stock units were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' 2018 Stock Incentive Plan.

    The option has a 10-year term and an exercise price of $24.97 per share, which is equal to the closing price per share of Arvinas' common stock on the grant date. The option vests over four years, with 25% of the original number of shares underlying the option vesting on the one-year anniversary of the date of grant and 75% of the original number of shares vesting monthly thereafter, and the restricted stock unit award vests in four equal installments on each one-year anniversary of Mr. Saik's employment start date until the fourth anniversary of Mr. Saik's start date, subject to his continued service with Arvinas through the applicable vesting dates. 

    About Arvinas

    Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit us on www.arvinas.com and connect with us on LinkedIn and X.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding Arvinas' preparation for its Phase 3 data readout; Arvinas' build out and scaling of financial systems and infrastructure necessary to support its ambitious growth plans and ensure as well as the company's position with respect to commercialization; and the potential therapeutic benefits of the product candidates in Arvinas' PROTAC® protein degrader pipeline. The words "believe," "expect," "may," "plan," "potential," "will," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made as a result of various risks and uncertainties, including but not limited to: Arvinas' approach to the discovery and development of product candidates based on its PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products; Arvinas' ability to protect its intellectual property position; whether cash and cash equivalent resources will be sufficient to fund Arvinas' foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date after the date of this release.

    Arvinas Contacts

    Investor Contact:

    Jeff Boyle, Arvinas Investor Relations

    +1 (347) 247-5089

    [email protected]

    Media Contact:

    Kirsten Owens, Arvinas Communications

    +1 (203) 584-0307

    [email protected]



    Primary Logo

    Get the next $ARVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARVN

    DatePrice TargetRatingAnalyst
    5/5/2025$11.00Buy → Hold
    Truist
    5/2/2025$10.00Buy → Hold
    Jefferies
    5/2/2025Buy → Hold
    TD Cowen
    3/13/2025$70.00 → $15.00Buy → Neutral
    Goldman
    3/12/2025$57.00 → $12.00Outperform → Neutral
    Wedbush
    3/11/2025Outperform → Perform
    Oppenheimer
    12/10/2024$69.00Buy
    BTIG Research
    11/18/2024$55.00Overweight
    Stephens
    More analyst ratings

    $ARVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm

      7/30/24 7:00:00 AM ET
      $ARVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

      - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D. "It is a pleasure to welcome Andrew as our new Chief Financial Officer," said John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas. "Andrew is a seasoned executive in biopharma finance with extensive

      6/24/24 4:37:13 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Loomis David K was granted 11,825 shares, increasing direct ownership by 63% to 30,688 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      5/13/25 5:18:50 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Saik Andrew was granted 59,600 shares, increasing direct ownership by 54% to 170,101 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      5/13/25 5:17:50 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Cacace Angela M was granted 59,600 shares, increasing direct ownership by 61% to 156,831 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      5/13/25 5:16:44 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ARVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

      Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancerData to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of MedicineArvinas will host a conference call t

      5/31/25 8:00:50 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Present at Jefferies Global Healthcare Conference

      NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 2:35 p.m. ET in New York City. A live audio webcast of the presentation will be available here and under "Events and Presentations" on the Investors and Media section of the Company's website. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threateni

      5/30/25 7:00:00 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clin

      5/1/25 7:00:24 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Truist with a new price target

      Truist downgraded Arvinas from Buy to Hold and set a new price target of $11.00

      5/5/25 8:28:44 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by TD Cowen

      TD Cowen downgraded Arvinas from Buy to Hold

      5/2/25 8:06:16 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Jefferies with a new price target

      Jefferies downgraded Arvinas from Buy to Hold and set a new price target of $10.00

      5/2/25 8:06:16 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Financials

    Live finance-specific insights

    See more
    • Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

      Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancerData to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of MedicineArvinas will host a conference call t

      5/31/25 8:00:50 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clin

      5/1/25 7:00:24 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to

      4/28/25 7:00:00 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.

      SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)

      5/15/25 1:56:31 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Arvinas Inc.

      10-Q - ARVINAS, INC. (0001655759) (Filer)

      5/1/25 5:16:13 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

      8-K - ARVINAS, INC. (0001655759) (Filer)

      5/1/25 7:05:21 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      11/14/24 1:22:38 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      11/14/24 7:00:23 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      9/10/24 10:30:07 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care